Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15646957 | 0.82 | HTT (0.35) | HSD11B1HTTMAPTTSHRKDM4E | |
| SCHEMBL16461536 | 0.76 | SMN1; SMN2 (0.33) | ALDH1A1SCN10ASMN1; SMN2 | |
| SCHEMBL16460110 | 0.74 | HTT (0.61) | HSD11B1HTTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL20151747 | 0.74 | LMNA (0.40) | HTTMAPTALDH1A1SMN1; SMN2PROKR1 | |
| SCHEMBL17541003 | 0.72 | — | — | |
| SCHEMBL263100 | 0.72 | — | — | |
| SCHEMBL16460670 | 0.72 | RAB9A (0.39) | HTTMAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15648089 | 0.71 | — | — | |
| SCHEMBL16632117 | 0.70 | IDO1 (0.33) | ALDH1A1SCN10A | |
| SCHEMBL18228019 | 0.68 | NNMT (0.54) | HSD11B1HTTMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057951-B1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2019-11-20 | — | — | EP | disclosed |
| EP-3057422-B1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| US-9284308-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV | 2016-03-15 | — | — | US | disclosed |
| US-9284308-B2 | Methylene linked quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV | 2016-03-15 | — | — | US | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105366-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | HSD11B1 801/4885HTT 2376/4885MAPT 2110/4885 |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | HSD11B1 697/4885HTT 2333/4885MAPT 2335/4885 |
| US-10201546-B2 | Quinolinyl modulators of RORγt | RORC, RORB, RORA | HSD11B1 353/4885HTT 2241/4885MAPT 1946/4885 |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | HSD11B1 697/4885HTT 2333/4885MAPT 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.